Quick Answer
Stoke Therapeutics, Inc. reported Total Revenue of $184.42 million for fiscal year 2025.
Stoke Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $184.42M | +404.5% |
| 2024 | $36.55M | +316.3% |
| 2023 | $8.78M | -29.2% |
| 2022 | $12.40M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.63M | +117.2% | -23.1% |
| June 30, 2025 | $13.82M | +186.0% | -91.3% |
| March 31, 2025 | $158.57M | +3661.1% | +3140.1% |
| September 30, 2024 | $4.89M | +47.9% | +1.3% |
| June 30, 2024 | $4.83M | +294.7% | +14.6% |
| March 31, 2024 | $4.22M | -18.2% | +27.4% |
| September 30, 2023 | $3.31M | +13.9% | +233.3% |
| June 30, 2023 | -$2.48M | -176.8% | -148.2% |
- Stoke Therapeutics, Inc. showed an increase of +404.5% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, Stoke Therapeutics, Inc.’s total revenue has grown by 1386.7% (from $12.40 million to $184.42 million).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: